Cover Image
市場調查報告書

液態切片的全球市場預測 ∼2021年:各癌症類型、循環生物標記 (循環腫瘤細胞、CTDNA)、產品、終端用戶

Liquid Biopsy Market by Cancer Type (Lung, Breast, Colorectal, Prostate, Liver), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA), Product (Instruments, Software), End User - Forecast to 2021

出版商 MarketsandMarkets 商品編碼 364533
出版日期 內容資訊 英文 161 Pages
訂單完成後即時交付
價格
Back to Top
液態切片的全球市場預測 ∼2021年:各癌症類型、循環生物標記 (循環腫瘤細胞、CTDNA)、產品、終端用戶 Liquid Biopsy Market by Cancer Type (Lung, Breast, Colorectal, Prostate, Liver), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA), Product (Instruments, Software), End User - Forecast to 2021
出版日期: 2016年07月21日 內容資訊: 英文 161 Pages
簡介

液態切片的市場在預測期間內預計以23.4%的年複合成長率 (CAGR) 發展,從2016年的5億8000萬美元,成長到2021年的16億6000萬美元的規模。對液態切片研究的供給資金的擴大和技術發展促進該市場的成長。

本報告提供全球液態切片的市場調查,市場及技術概要,產業趨勢,影響市場成長因素及市場機會分析,各癌症類型、循環生物標記、產品&服務、終端用戶、地區/主要國家趨勢與市場規模的變化與預測,競爭環境,以及主要企業的簡介等彙整。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 液態切片:市場概要
  • 地區市場:各循環生物標記
  • 市場規模的實際成果、預測:各終端用戶
  • 市場規模的實際成果、預測:各產品
  • 市場規模的實際成果、預測:各循環生物標記
  • 地區概要

第5章 液態切片的全球市場:概要

  • 簡介
  • 市場動態
    • 推動因素
    • 阻礙因素
    • 機會
    • 課題

第6章 液態切片的全球市場:產業趨勢

  • 簡介
  • 法律規章上的認證流程
  • 現在進行中的主要的臨床實驗
  • 主要的資金籌措活動

第7章 液態切片的全球市場:各癌症類型

  • 簡介
  • 肺癌
  • 乳癌
  • 大腸癌
  • 前列腺癌
  • 肝癌
  • 其他

第8章 液態切片的全球市場:各循環生物標記

  • 簡介
  • 循環腫瘤細胞
  • 細胞外小胞
  • 循環腫瘤原來DNA (CTDNA)
  • 其他

第9章 液態切片的全球市場:各產品與服務

  • 簡介
  • 試劑
  • 設備
  • 服務&軟體

第10章 液態切片的全球市場:各終端用戶

  • 簡介
  • 索引實驗室
  • 醫院、醫生的實驗室
  • 學術、研究中心
  • 其他

第11章 液態切片的全球市場:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
  • 亞太地區
  • 其他地區

第12章 競爭環境

  • 概要
  • 競爭情形、趨勢
    • 協定、聯盟、合作
    • 新產品的投入
    • 收購
    • 其他

第13章 企業簡介

  • 簡介
  • BIOCEPT, INC.
  • QIAGEN
  • F. HOFFMANN-LA ROCHE AG
  • BIO-RAD LABORATORIES INC.
  • MYRIAD GENETICS
  • JANSSEN DIAGNOSTICS, LLC.
  • TR0VAGENE INC.
  • GUARDANT HEALTH INC.
  • FRAUNHOFER-GESELLSCHAFT
  • MDX HEALTH SA
    • 簡介
    • 產品與服務
    • 策略
    • 分析師的見解
    • 發展趨勢
    • MnM的見解等

第14章 附錄

目錄
Product Code: MD 4456

Growing Funding for Research on Liquid Biopsy and Technological Advancements to Boost the Growth of the Liquid Biopsy Market

The liquid biopsy market is expected to reach USD 1.66 billion by 2021 from USD 0.58 billion in 2016, growing at a CAGR of 23.4% during the forecast period of 2016 to 2021. Liquid biopsy is a non-invasive alternative to invasive solid tumor biopsies; it detects biomarkers from primary tumors and from metastatic sites to ascertain genetic information about tumors.

This report segments the liquid biopsy market on the basis of cancer type, circulating biomarkers, end users, products & services, and regions.

Based on cancer type, the market is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, and other cancers (melanoma, bladder cancer, and ovarian cancer). Based on circulating biomarkers, the liquid biopsy market is segmented into circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles (EVs), and other biomarkers (circulating RNA and protein). The circulating tumor cells segment is expected to account for the largest share of the global liquid biopsy market in 2016, followed by the circulating tumor DNA segment.

Based on end user, the liquid biopsy market is classified into hospital/physician laboratories, reference laboratories, academic and research centers and other end users. The other end-users segment includes public health laboratories, pathology laboratories, and small molecular laboratories. Similarly, based on products and services, the liquid biopsy market is segmented into instruments, reagents, and services and software.

A number of factors, such as technological advancements, increasing number of new cancer cases, benefits of liquid biopsy over solid tumor biopsy, availability of funding, and growing awareness about liquid biopsy through conferences and government initiatives are driving the growth of the liquid biopsy market. However, the unclear regulatory and reimbursement scenario is one of the major factors restraining the growth of this market.

Biocept Inc. (U.S.), Myriad Genetics (U.S.), QIAGEN (Netherlands), Roche (Switzerland), Bio-Rad Laboratories Inc. (U.S.), Trovagene Inc. (U.S.), Guardant Health, Inc. (U.S.), Janssen Diagnostics, LLC (U.S.), Fraunhofer-Gesellschaft (Germany), and MDxHealth SA (U.S.) are the major players in the liquid biopsy market.

Reasons to Buy the Report:

From an insight perspective, this research report focuses on various levels of analysis-industry analysis (industry trends) and company profiles, which together comprise and discuss the basic views on the competitive landscape; emerging and high-growth segments of the liquid biopsy market; high-growth regions; and market drivers, restraints, and opportunities.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on products offered by the top players in the global liquid biopsy market
  • Product Development/Innovation: Detailed insights on the upcoming technologies, research & development activities, and new product launches in the liquid biopsy market
  • Market Development: Comprehensive information about lucrative emerging markets-the report analyzes the markets for liquid biopsy across various regions
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the global liquid biopsy market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the liquid biopsy market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKETS SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. MARKET BREAKDOWN AND DATA TRIANGULATION
    • 2.2.1. KEY DATA FROM SECONDARY SOURCES
    • 2.2.2. KEY DATA FROM PRIMARY SOURCES
    • 2.2.3. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CURRENT SCENARIO
  • 3.3. FUTURE OUTLOOK
  • 3.4. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. LIQUID BIOPSY: MARKET OVERVIEW
  • 4.2. GEOGRAPHIC ANALYSIS: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER
  • 4.3. LIQUID BIOPSY MARKET SIZE, BY END USER, 2016 VS. 2021
  • 4.4. LIQUID BIOPSY MARKET SIZE, BY PRODUCT, 2016 VS. 2021
  • 4.5. LIQUID BIOPSY MARKET SIZE, BY CIRCULATING BIOMARKER, 2016 VS. 2021
  • 4.6. GEOGRAPHICAL SNAPSHOT OF THE LIQUID BIOPSY MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. MARKET DRIVERS
      • 5.2.1.1. Increasing number of new cancer cases
      • 5.2.1.2. Benefits of liquid biopsy over surgical biopsy
      • 5.2.1.3. Technological advancements to boost market growth
      • 5.2.1.4. Availability of funding for liquid biopsy research
      • 5.2.1.5. Initiatives to increase awareness on liquid biopsy
    • 5.2.2. MARKET RESTRAINTS
      • 5.2.2.1. Low Sensitivity and specificity
    • 5.2.3. MARKET OPPORTUNITIES
      • 5.2.3.1. Focus on inorganic strategies
    • 5.2.4. MARKET CHALLENGES
      • 5.2.4.1. Unclear Regulatory and reimbursement scenario

6. INDUSTRY INSIGHTS

  • 6.1. INTRODUCTION
  • 6.2. REGULATORY APPROVAL PROCESS
  • 6.3. MAJOR ONGOING CLINICAL TRIALS IN THE LIQUID BIOPSY MARKET
  • 6.4. MAJOR FUNDING ACTIVITIES IN THE LIQUID BIOPSY MARKET

7. LIQUID BIOPSY MARKET, BY CANCER TYPE

  • 7.1. INTRODUCTION
    • 7.1.1. LUNG CANCER
  • 7.2. BREAST CANCER
    • 7.2.1. COLORECTAL CANCER
    • 7.2.2. PROSTATE CANCER
    • 7.2.3. LIVER CANCER
    • 7.2.4. OTHER CANCERS

8. LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER

  • 8.1. INTRODUCTION
  • 8.2. CIRCULATING TUMOR CELLS
  • 8.3. EXTRACELLULAR VESICLES
  • 8.4. CIRCULATING TUMOR DNA (CTDNA)
  • 8.5. OTHER BIOMARKERS

9. LIQUID BIOPSY MARKET, BY PRODUCTS AND SERVICES

  • 9.1. INTRODUCTION
    • 9.1.1. REAGENTS
  • 9.2. INSTRUMENTS
    • 9.2.1. SERVICES & SOFTWARE

10. LIQUID BIOPSY MARKET, BY END USER

  • 10.1. INTRODUCTION
  • 10.2. REFERENCE LABORATORIES
    • 10.2.1. HOSPITALS AND PHYSICIAN LABORATORIES
    • 10.2.2. ACADEMIC AND RESEARCH CENTERS
    • 10.2.3. OTHER END USERS

11. LIQUID BIOPSY MARKET, BY REGION

  • 11.1. INTRODUCTION
  • 11.2. NORTH AMERICA
    • 11.2.1. U.S.
    • 11.2.2. CANADA
  • 11.3. EUROPE
  • 11.4. ASIA-PACIFIC
  • 11.5. REST OF THE WORLD (ROW)

12. COMPETITIVE LANDSCAPE

  • 12.1. OVERVIEW
  • 12.2. COMPETITIVE SITUATION AND TRENDS
    • 12.2.1. AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
    • 12.2.2. NEW PRODUCT LAUNCHES
    • 12.2.3. ACQUISITIONS
    • 12.2.4. OTHER DEVELOPMENTS

13. COMPANY PROFILES (Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*

  • 13.1. INTRODUCTION
  • 13.2. BIOCEPT, INC.
  • 13.3. QIAGEN
  • 13.4. F. HOFFMANN-LA ROCHE AG
  • 13.5. BIO-RAD LABORATORIES INC.
  • 13.6. MYRIAD GENETICS
  • 13.7. JANSSEN DIAGNOSTICS, LLC.
  • 13.8. TR0VAGENE INC.
  • 13.9. GUARDANT HEALTH INC.
  • 13.10. FRAUNHOFER-GESELLSCHAFT
  • 13.11. MDX HEALTH SA

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

14. APPENDIX

  • 14.1. INSIGHTS OF INDUSTRY EXPERTS
  • 14.2. DISCUSSION GUIDE
  • 14.3. OTHER DEVELOPMENTS
  • 14.4. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.5. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 14.6. AVAILABLE CUSTOMIZATIONS
  • 14.7. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: LIQUID BIOPSY PRODUCTS LAUNCHED IN RECENT YEARS
  • TABLE 2: FUNDS PROVIDED FOR LIQUID BIOPSY, 2013-2016
  • TABLE 3: CONFERENCES AND AWARENESS PROGRAMS ON LIQUID BIOPSY
  • TABLE 4: LIQUID BIOPSY MARKET: INORGANIC STRATEGIES (2015-16)
  • TABLE 5: LIQUID BIOPSY CLINICAL TRIALS
  • TABLE 6: FUNDING IN LIQUID BIOPSY MARKET
  • TABLE 7: LIQUID BIOPSY MARKET SIZE, BY CANCER TYPE, 2014-2021 (USD MILLION)
  • TABLE 8: GLOBAL LIQUID BIOPSY MARKET SIZE FOR LUNG CANCER, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 9: NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR LUNG CANCER, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 10: IMPACT OF AGING ON BREAST CANCER DEVELOPMENT
  • TABLE 11: GLOBAL LIQUID BIOPSY MARKET SIZE FOR BREAST CANCER, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 12: NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR BREAST CANCER, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 13: GLOBAL LIQUID BIOPSY MARKET SIZE FOR COLORECTAL CANCER, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 14: NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR COLORECTAL CANCER, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 15: GLOBAL LIQUID BIOPSY MARKET SIZE FOR PROSTATE CANCER, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 16: NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR PROSTATE CANCER, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 17: GLOBAL LIQUID BIOPSY MARKET SIZE FOR LIVER CANCER, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 18: NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR LIVER CANCER, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 19: GLOBAL LIQUID BIOPSY MARKET SIZE FOR OTHER CANCERS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 20: NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR OTHER CANCERS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 21: LIQUID BIOPSY MARKET SIZE, BY CIRCULATING BIOMARKER, 2014-2021 (USD MILLION)
  • TABLE 22: LIQUID BIOPSY MARKET SIZE FOR CIRCULATING TUMOR CELLS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 23: NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 24: LIQUID BIOPSY MARKET SIZE FOR EXTRACELLULAR VESICLES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 25: NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 26: LIQUID BIOPSY MARKET SIZE FOR CIRCULATING TUMOR DNA, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 27: NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 28: LIQUID BIOPSY MARKET SIZE FOR OTHER BIOMARKERS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 29: NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR OTHER BIOMARKERS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 30: GLOBAL LIQUID BIOPSY MARKET SIZE, BY PRODUCTS & SERVICES, 2014-2021 (USD MILLION)
  • TABLE 31: GLOBAL LIQUID BIOPSY REAGENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 32: NORTH AMERICA: LIQUID BIOPSY REAGENTS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 33: GLOBAL LIQUID BIOPSY INSTRUMENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 34: NORTH AMERICA: LIQUID BIOPSY INSTRUMENTS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 35: GLOBAL LIQUID BIOPSY SERVICES & SOFTWARE MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 36: NORTH AMERICA: LIQUID BIOPSY SERVICES & SOFTWARE MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 37: LIQUID BIOPSY MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 38: LIQUID BIOPSY MARKET SIZE FOR REFERENCE LABORATORIES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 39: NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR REFERENCE LABORATORIES, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 40: LIQUID BIOPSY MARKET SIZE FOR HOSPITALS AND PHYSICIAN LABORATORIES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 41: NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR HOSPITALS AND PHYSICIAN LABORATORIES, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 42: LIQUID BIOPSY MARKET SIZE FOR ACADEMIC AND RESEARCH CENTERS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 43: NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR ACADEMIC AND RESEARCH CENTERS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 44: LIQUID BIOPSY MARKET SIZE FOR OTHER END USERS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 45: NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR OTHER END USERS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 46: LIQUID BIOPSY MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 47: NORTH AMERICA: LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 48: NORTH AMERICA: LIQUID BIOPSY MARKET SIZE, BY TYPE OF CANCER, 2014-2021 (USD MILLION)
  • TABLE 49: NORTH AMERICA: LIQUID BIOPSY MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 50: NORTH AMERICA: LIQUID BIOPSY MARKET SIZE, BY CIRCULATING BIOMARKER, 2014-2021 (USD MILLION)
  • TABLE 51: NORTH AMERICA: LIQUID BIOPSY MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 52: U.S.: LIQUID BIOPSY MARKET SIZE, BY TYPE OF CANCER, 2014-2021 (USD MILLION)
  • TABLE 53: U.S.: LIQUID BIOPSY MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 54: U.S.: LIQUID BIOPSY MARKET SIZE, BY CIRCULATING BIOMARKER, 2014-2021 (USD MILLION)
  • TABLE 55: U.S.: LIQUID BIOPSY MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 56: CANADA: LIQUID BIOPSY MARKET SIZE, BY TYPE OF CANCER, 2014-2021 (USD MILLION)
  • TABLE 57: CANADA: LIQUID BIOPSY MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 58: CANADA: LIQUID BIOPSY MARKET SIZE, BY CIRCULATING BIOMARKER, 2014-2021 (USD MILLION)
  • TABLE 59: CANADA: LIQUID BIOPSY MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 60: EUROPE: LIQUID BIOPSY MARKET SIZE, BY TYPE OF CANCER, 2014-2021 (USD MILLION)
  • TABLE 61: EUROPE: LIQUID BIOPSY MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 62: EUROPE: LIQUID BIOPSY MARKET SIZE, BY CIRCULATING BIOMARKER, 2014-2021 (USD MILLION)
  • TABLE 63: EUROPE: LIQUID BIOPSY MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 64: ASIA-PACIFIC: LIQUID BIOPSY MARKET SIZE, BY TYPE OF CANCER, 2014-2021 (USD MILLION)
  • TABLE 65: ASIA-PACIFIC: LIQUID BIOPSY MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 66: ASIA-PACIFIC: LIQUID BIOPSY MARKET SIZE, BY CIRCULATING BIOMARKER, 2014-2021 (USD MILLION)
  • TABLE 67: ASIA-PACIFIC: LIQUID BIOPSY MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 68: ROW: LIQUID BIOPSY MARKET SIZE, BY TYPE OF CANCER, 2014-2021 (USD MILLION)
  • TABLE 69: ROW: LIQUID BIOPSY MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 70: ROW: LIQUID BIOPSY MARKET SIZE, BY CIRCULATING BIOMARKER, 2014-2021 (USD MILLION)
  • TABLE 71: ROW: LIQUID BIOPSY MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 72: AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS, 2013-2016
  • TABLE 73: NEW PRODUCT LAUNCHES, 2013-2016
  • TABLE 74: ACQUISITIONS, 2013-2016
  • TABLE 75: OTHER DEVELOPMENTS, 2013-2016

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: EPIDEMIOLOGY MODEL
  • FIGURE 3: MARKET SIZE ESTIMATION AND DATA TRIANGULATION
  • FIGURE 4: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5: MARKET DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: LIQUID BIOPSY MARKET SIZE, BY PRODUCT, 2016 VS. 2021 (USD MILLION)
  • FIGURE 7: LIQUID BIOPSY MARKET SIZE, BY CANCER TYPE, 2016 VS. 2021 (USD MILLION)
  • FIGURE 8: LIQUID BIOPSY MARKET SIZE, BY CIRCULATING BIOMARKER, 2016 VS. 2021 (USD MILLION)
  • FIGURE 9: LIQUID BIOPSY MARKET SIZE, BY END USER, 2016 VS. 2021 (USD MILLION)
  • FIGURE 10: GEOGRAPHICAL SNAPSHOT OF THE LIQUID BIOPSY MARKET, 2016
  • FIGURE 11: INCREASING NUMBER OF NEW CANCER CASES-PRIMARY GROWTH DRIVER FOR THE LIQUID BIOPSY MARKET
  • FIGURE 12: CIRCULATING TUMOR CELLS SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2016
  • FIGURE 13: REFERENCE LABORATORIES SEGMENT WILL CONTINUE TO DOMINATE THE LIQUID BIOPSY MARKET IN 2021
  • FIGURE 14: REAGENTS SEGMENT DOMINATES THE LIQUID BIOPSY MARKET IN 2016
  • FIGURE 15: CIRCULATING TUMOR CELLS SEGMENT ACCOUNTS FOR THE LARGEST MARKET SHARE IN 2016
  • FIGURE 16: ASIA-PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD
  • FIGURE 17: LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, CHALLENGES
  • FIGURE 18: INCREASING NUMBER OF NEW CANCER CASES WORLDWIDE (2012-2020)
  • FIGURE 19: COST COMPARISON BETWEEN LIQUID AND INCISIONAL BIOPSY
  • FIGURE 20: RELATIONSHIP BETWEEN LIQUID BIOPSY SENSITIVITY AND NUMBER OF METASTATIC SITES
  • FIGURE 21: DISCOVERY AND DEVELOPMENT OF MEDICAL DEVICES
  • FIGURE 22: NEW CANCER CASES, BY COUNTRY (2012)
  • FIGURE 23: NEW CANCER CASES, BY COUNTRY (2020)
  • FIGURE 24: NEW CANCER CASES WORLDWIDE (2012 VS. 2015 VS. 2020)
  • FIGURE 25: LUNG CANCER WILL CONTINUE TO ACCOUNT FOR THE LARGEST SHARE IN 2021
  • FIGURE 26: NORTH AMERICA WILL CONTINUE TO DOMINATE THE LIQUID BIOPSY MARKET FOR LUNG CANCER BY 2021
  • FIGURE 27: ASIA-PACIFIC OFFERS LUCRATIVE OPPORTUNITIES IN THE LIQUID BIOPSY MARKET FOR BREAST CANCER
  • FIGURE 28: NORTH AMERICA WILL CONTINUE TO LEAD THE LIQUID BIOPSY MARKET FOR COLORECTAL CANCER IN 2021
  • FIGURE 29: NORTH AMERICA WILL CONTINUE TO LEAD THE LIQUID BIOPSY MARKET FOR PROSTATE CANCER IN 2021
  • FIGURE 30: NORTH AMERICA WILL CONTINUE TO LEAD THE LIQUID BIOPSY MARKET FOR LIVER CANCER IN 2021
  • FIGURE 31: NEW CASES OF OTHER CANCER TYPES WORLDWIDE (2012-2020)
  • FIGURE 32: NORTH AMERICA WILL CONTINUE TO LEAD THE OTHER CANCERS MARKET IN 2021
  • FIGURE 33: CIRCULATING TUMOR CELLS TO ACCOUNT FOR THE LARGEST SHARE OF THE LIQUID BIOPSY MARKET
  • FIGURE 34: NORTH AMERICA WILL CONTINUE TO ACCOUNT FOR LARGEST MARKET SHARE IN 2021
  • FIGURE 35: NORTH AMERICA TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2021
  • FIGURE 36: NORTH AMERICA WILL CONTINUE TO ACCOUNT FOR LARGEST MARKET SHARE IN 2021
  • FIGURE 37: NORTH AMERICA TO DOMINATE THE MARKET FOR OTHER BIOMARKERS
  • FIGURE 38: THE REAGENTS PRODUCT SEGMENT WILL CONTINUE TO ACCOUNT FOR THE LARGEST SHARE OF THE MARKET IN THE FORECAST PERIOD
  • FIGURE 39: NORTH AMERICA WILL CONTINUE TO DOMINATE THE MARKET FOR LIQUID BIOPSY REAGENTS DURING THE FORECAST PERIOD
  • FIGURE 40: ASIA-PACIFIC TO WITNESS HIGHEST GROWTH IN THE LIQUID BIOPSY INSTRUMENTS MARKET BY 2021
  • FIGURE 41: NORTH AMERICA WILL CONTINUE TO DOMINATE THE MARKET FOR LIQUID BIOPSY SERVICES & SOFTWARE IN 2021
  • FIGURE 42: REFERENCE LABORATORIES SEGMENT WILL CONTINUE TO DOMINATE THE MARKET
  • FIGURE 43: ASIA-PACIFIC REFERENCE LABORATORIES END-USER SEGMENT TO SHOW HIGHEST GROWTH
  • FIGURE 44: NORTH AMERICA, THE LARGEST SEGMENT IN THE HOSPITAL / PHYSICIAN LABORATORIES MARKET
  • FIGURE 45: NORTH AMERICA WILL CONTINUE TO DOMINATE THE LIQUID BIOPSY MARKET FOR ACADEMIC AND RESEARCH CENTERS
  • FIGURE 46: ASIA-PACIFIC TO GROW AT THE HIGHEST RATE IN THE LIQUID BIOPSY MARKET FOR OTHER END USERS
  • FIGURE 47: NORTH AMERICA TO ACCOUNT FOR THE LARGEST SHARE OF THE LIQUID BIOPSY MARKET IN 2016
  • FIGURE 48: NORTH AMERICA LIQUID BIOPSY MARKET SNAPSHOT
  • FIGURE 49: NORTH AMERICAN LUNG CANCER SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE LIQUID BIOPSY MARKET IN 2016
  • FIGURE 50: CIRCULATING TUMOR CELLS SEGMENT EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICAN LIQUID BIOPSY MARKET IN 2016
  • FIGURE 51: LUNG CANCER TO DOMINATE U.S. LIQUID BIOPSY MARKET, BY CANCER TYPE, TILL 2021
  • FIGURE 52: REFERENCE LABORATORIES END-USER SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. LIQUID BIOPSY MARKET IN 2016
  • FIGURE 53: LUNG CANCER WILL CONTINUE TO DOMINATE THE CANADIAN LIQUID BIOPSY MARKET TILL 2021
  • FIGURE 54: REAGENTS ACCOUNT FOR THE LARGEST SHARE OF THE CANADIAN LIQUID BIOPSY MARKET IN 2016
  • FIGURE 55: EUROPE: CANCER FREQUENCY, BY COUNTRY, 2012 (PER 100,000 POPULATION)
  • FIGURE 56: MEDICAL INSURANCE COVERAGE OF MAJOR EUROPEAN COUNTRIES, 2013
  • FIGURE 57: LUNG CANCER SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE LIQUID BIOPSY MARKET IN 2016
  • FIGURE 58: REFERENCE LABORATORIES, THE LARGEST END-USER SEGMENT IN THE EUROPEAN MARKET
  • FIGURE 59: ASIA-PACIFIC LIQUID BIOPSY MARKET SNAPSHOT
  • FIGURE 60: LUNG CANCER IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC LIQUID BIOPSY MARKET IN 2016
  • FIGURE 61: CIRCULATING TUMOR CELLS SEGMENT TO DOMINATE ASIA-PACIFIC LIQUID BIOPSY MARKET IN 2016
  • FIGURE 62: LUNG CANCER WILL DOMINATE THE ROW LIQUID BIOPSY MARKET TILL 2021
  • FIGURE 63: REAGENTS PRODUCT SEGMENT TO COMMAND LARGEST SHARE OF THE ROW LIQUID BIOPSY MARKET
  • FIGURE 64: COMPANIES ADOPTED AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS AS THEIR KEY GROWTH STRATEGY OVER THE LAST FOUR YEARS (2013-2016)
  • FIGURE 65: AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS - KEY GROWTH STRATEGIES ADOPTED BY PLAYERS IN THE LIQUID BIOPSY MARKET
  • FIGURE 66: GEOGRAPHIC REVENUE MIX OF TOP FOUR MARKET PLAYERS
  • FIGURE 67: BIOCEPT, INC.: COMPANY SNAPSHOT
  • FIGURE 68: QIAGEN: COMPANY SNAPSHOT
  • FIGURE 69: COMPANY SNAPSHOT: F. HOFFMANN-LA ROCHE AG
  • FIGURE 70: COMPANY SNAPSHOT: BIO-RAD LABORATORIES INC.
  • FIGURE 71: MYRIAD GENETICS: COMPANY SNAPSHOT
  • FIGURE 72: JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • FIGURE 73: TRAVOGENE INC.: COMPANY SNAPSHOT
  • FIGURE 74: MDX HEALTH: COMPANY SNAPSHOT
Back to Top